Bovine Thymus Capsules (Bos taurus)
Bovine thymus capsules are derived from the thymus gland of cattle (Bos taurus) and contain thymic peptides such as thymosin, thymulin, and thymopoietin that theoretically support T-cell maturation and immune modulation. The primary proposed mechanism involves these peptides interacting with lymphocyte differentiation pathways, though robust human clinical evidence remains limited.

Origin & History
Bovine Thymus Capsules are dietary supplements derived from the thymus glands of young calves (Bos taurus), processed through defatted vacuum-drying or lyophilization into powder form. The glands are sourced from veterinarian-inspected animals in BSE-negligible or controlled-risk countries per OIE standards, then encapsulated for oral consumption.
Historical & Cultural Context
No traditional medicine use (Ayurveda, TCM) is documented in available sources. Modern use stems from 20th-century understanding of the thymus's role in T-cell development, with clinical interest in thymic peptides for immune support and neuroprotection based on age-related thymus atrophy.
Health Benefits
• May support immune function through T-cell maturation enhancement (theoretical mechanism, no human RCTs identified) • Potential neuroprotective effects via GABA pathway modulation (preliminary evidence from one mouse study, PMID: 41624337) • Possible benefit for airway infections when using pharmaceutical-grade extracts like Thymomodulin (limited clinical data) • May help with allergic conditions in children at 120 mg/day doses (based on Thymomodulin studies, not standard supplements) • Theoretical age-related immune support due to thymus atrophy compensation (no direct human evidence)
How It Works
Bovine thymus extract contains bioactive peptides—including thymosin alpha-1, thymulin (a zinc-dependent nonapeptide), and thymopoietin—that are proposed to bind lymphocyte surface receptors and promote the differentiation of immature T-cell precursors into functional CD4+ and CD8+ T-cells. Thymulin specifically requires zinc as a cofactor to become biologically active and may upregulate interleukin-2 (IL-2) signaling, enhancing T-cell proliferative responses. Preliminary mouse model data (PMID: 41624337) also suggests possible modulation of GABAergic pathways, potentially influencing neuroinflammatory signaling, though this mechanism has not been confirmed in humans.
Scientific Research
Clinical evidence is extremely limited, with no large-scale RCTs or meta-analyses identified for immune support, cancer, or anti-aging claims. One preclinical study (PMID: 41624337) in aging mice showed thymus nuclear fraction increased GAD65/GAD67 enzymes and GABA_A receptors, but human data is absent. Some studies used pharmaceutical-grade Thymomodulin for airway infections, but over-the-counter supplements lack equivalent data.
Clinical Summary
Human clinical evidence for bovine thymus capsules is sparse; no large-scale randomized controlled trials (RCTs) have been identified specifically for this oral supplement form in healthy adults. Early pharmaceutical-grade thymic extract preparations (e.g., Thymostimulin) were studied in small European trials during the 1980s–1990s for recurrent respiratory infections, with some showing reduced infection frequency, but these involved injectable or standardized extracts rather than over-the-counter capsules. One mouse study (PMID: 41624337) provided preliminary neuroprotective data via GABA pathway modulation, representing very low-quality evidence by GRADE standards. Overall, the evidence base is insufficient to establish efficacy for any specific indication in humans, and outcomes have not been quantified in rigorous modern trial designs.
Nutritional Profile
Bovine thymus tissue is primarily composed of protein (approximately 60-70% of dry weight), with the remainder consisting of lipids (~15-20% of dry weight), carbohydrates (~5-10%), and ash/minerals (~5%). Key bioactive protein fractions include thymosin alpha-1, thymosin beta-4, thymulin (a zinc-dependent nonapeptide), thymopoietin, and thymic humoral factor (THF). Zinc is a critical associated micronutrient essential for thymulin bioactivity, with thymus tissue containing approximately 20-40 mcg zinc per gram of dry tissue. Additional minerals present include iron (~2-4 mg/100g), selenium (~10-20 mcg/100g), and phosphorus (~150-200 mg/100g). Nucleotides and nucleosides are present as bioactive compounds, contributing to immune-signaling potential. Lipid fractions contain phospholipids and sphingomyelin, which may contribute to membrane-supportive effects. Typical commercial capsules contain 250-500 mg of desiccated thymus concentrate per capsule. Bioavailability of intact peptides (e.g., thymosin fractions) via oral route is considered low due to gastrointestinal proteolytic degradation; however, smaller peptide fragments and free amino acids derived from digestion remain bioavailable. Zinc bioavailability from thymus tissue is estimated at 20-30%, consistent with animal-source zinc. No significant vitamin content has been documented in commercially processed thymus concentrates.
Preparation & Dosage
Clinically studied doses for pharmaceutical-grade calf thymus extract (Thymomodulin) include 80-120 mg/day orally for up to 4 months in adults and children. Injectable forms used 10 mg three times weekly for cardiomyopathy. No standardization exists for commercial bovine thymus capsules. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
Zinc, Vitamin C, Vitamin D3, Astragalus, Selenium
Safety & Interactions
Bovine thymus capsules carry a theoretical risk of prion transmission (bovine spongiform encephalopathy concerns), though commercially sourced products from BSE-certified herds are considered low risk by most regulatory bodies. Individuals with autoimmune conditions should use caution, as immune-stimulating peptides like thymosin alpha-1 could theoretically exacerbate dysregulated immune activity. Concurrent use with immunosuppressant drugs (e.g., cyclosporine, tacrolimus, corticosteroids) may produce antagonistic interactions, potentially reducing transplant or autoimmune medication effectiveness. Safety data in pregnancy and lactation is absent, and use is not recommended in these populations until evidence is established.